{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:27Z","timestamp":1793394507422,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060459"],"award-info":[{"award-number":["82060459"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajps.2025.101095","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:26:40Z","timestamp":1760545600000},"page":"101095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Guangrui","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongfei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengtuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-591X","authenticated-orcid":false,"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajps.2025.101095_bib0001","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2025.101095_bib0002","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2025.101095_bib0003","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajps.2025.101095_bib0004","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 Mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?\u2020","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajps.2025.101095_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ajps.2025.101095_bib0006","first-page":"165","article-title":"Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajps.2025.101095_bib0007","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ajps.2025.101095_bib0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/antib12040072","article-title":"Trends in the development of antibody-drug conjugates for cancer therapy","volume":"12","author":"Song","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ajps.2025.101095_bib0009","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/curroncol31040172","article-title":"Antibody-drug conjugates in the treatment of genitourinary cancers: an updated review of data","volume":"31","author":"Nathan","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ajps.2025.101095_bib0010","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1093\/annonc\/mdx541","article-title":"The antibody-drug conjugate target landscape across a broad range of tumour types","volume":"28","author":"Moek","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajps.2025.101095_bib0011","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","article-title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody\u2013drug conjugate, in patients with advanced or metastatic cancer","volume":"39","author":"Kollmannsberger","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ajps.2025.101095_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107802","article-title":"FL118: a potential bladder cancer therapeutic compound targeting H2A.X identified through library screening","volume":"153","author":"Fan","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.ajps.2025.101095_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ajps.2025.101095_bib0014","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.cell.2023.02.038","article-title":"SnapShot: cancer chemotherapy","volume":"186","author":"Falzone","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ajps.2025.101095_bib0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajps.2025.101095_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ajps.2025.101095_bib0017","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study","volume":"3","author":"Hu","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ajps.2025.101095_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajps.2025.101095_bib0019","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajps.2025.101095_bib0020","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajps.2025.101095_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087625000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087625000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:39:54Z","timestamp":1767011994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087625000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1818087625000790"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2025.101095","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2025.101095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University.","name":"copyright","label":"Copyright"}],"article-number":"101095"}}